Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Creo Medical ( (GB:CREO) ) is now available.
Creo Medical will showcase its endoscopic technology at Digestive Disease Week 2026 in Chicago, where leading gastroenterologists will present real-world data on procedures using its CROMA advanced energy platform and Speedboat devices. The studies highlight high technical success, R0 resections without postoperative complications and potential improvements in colorectal cancer margins and peroral endoscopic myotomy, reinforcing clinical validation that could support wider adoption of Creo’s minimally invasive solutions.
One presentation will detail sequential intermuscular and full thickness dissection using bipolar and microwave-assisted endoscopic submucosal dissection, underscoring the safety and precision of CROMA-powered procedures. Additional data from more than 600 Speedboat-assisted colorectal cancer cases and a 75-patient POEM series point to operational efficiencies, such as fewer instrument exchanges, and may strengthen Creo’s positioning in advanced therapeutic endoscopy and hospital decision-making on endoscopic technologies.
Spark’s Take on CREO Stock
According to Spark, TipRanks’ AI Analyst, CREO is a Neutral.
The score is held back primarily by poor financial performance (sharp revenue decline, large losses, and continued cash burn). Technicals are a partial offset with strong trend and positive MACD, but very overbought RSI increases near-term risk. Valuation impact is neutral since P/E and dividend yield were not provided.
To see Spark’s full report on CREO stock, click here.
More about Creo Medical
Creo Medical Group is a UK-based medical device company specialising in minimally invasive electrosurgical technologies for endoscopy, with a focus on treating pre-cancer and cancer patients. Its CROMA platform, powered by Kamaptive technology, integrates bipolar radiofrequency and microwave energy to enable precise cutting, coagulation, dissection and ablation, aiming to make procedures safer, less invasive and more cost-efficient.
Average Trading Volume: 763,831
Technical Sentiment Signal: Strong Sell
Current Market Cap: £50.53M
For detailed information about CREO stock, go to TipRanks’ Stock Analysis page.